tbuckley/cabot-search huggingface dataset:
P2-324: Is there a survival benefit in patients with NSCLC under taxane administration? A multi-centre study
Authors: Kostas Zarogoulidis, Theodore Kontakiotis, Ellada Eleftheriadou, George Balassoulis, Alexandra Kosma, Klio Eleftheriou, Theodora Tsouda, Pavlos Zarogoulidis, Efi Kalaitzidou, Efi Milonaki
Journal: Journal of Thoracic Oncology (2007)
Late acute graft-versus-host disease: a prospective analysis of clinical outcomes and circulating angiogenic factors
Authors: Shernan G. Holtan, Nandita Khera, John E. Levine, Xiaoyu Chai, Barry Storer, Hien D. Liu, Yoshihiro Inamoto, George L. Chen, Sebastian Mayer, Mukta Arora, Jeanne Palmer, Mary E. D. Flowers, Corey S. Cutler, Alexander Lukez, Sally Arai, Aleksandr Lazaryan, Laura F. Newell, Christa Krupski, Madan H. Jagasia, Iskra Pusic, William Wood, Anne S. Renteria, Gregory Yanik, William J. Hogan, Elizabeth Hexner, Francis Ayuk, Ernst Holler, Phandee Watanaboonyongcharoen, Yvonne A. Efebera, James L. M. Ferrara, Angela Panoskaltsis-Mortari, Daniel Weisdorf, Stephanie J. Lee, Joseph Pidala
Journal: Blood (2016)
The STRATUS trial (MM-010): A single-arm phase 3b study of pomalidomide plus low-dose dexamethasone (POM + LoDEX) in refractory or relapsed and refractory multiple myeloma.
Authors: Meletios A. Dimopoulos, Katja C. Weisel, Michele Cavo, Paolo Corradini, Michel Delforge, Gareth J Morgan, Markus Hansson, Antonio Palumbo, Enrique M. Ocio, Mathew Simcock, Neil Miller, Ana Slaughter, Nicolas Leupin, Zariana G. Nikolova, Philippe Moreau
Journal: Journal of Clinical Oncology (2014)

TPS8625 Background: POM is a distinct oral IMiD immunomodulatory agent with direct anti-myeloma, stromal cell support-inhibitory, and immune-modulating activities. In the phase 3 MM-003 trial, POM + LoDEX significantly extended progression-free survival (PFS) and overall survival (OS) vs. high-dose dexamethasone in patients (pts) who failed bortezomib (BORT) and lenalidomide (LEN) treatment (Tx; Dimopoulos, ASH 2013). STRATUS is a multicenter, single-arm, open-label phase 3b trial with > 85 sites across Europe to further evaluate safety and efficacy and explore cytogenetics, pharmacokinetics (PK), and biomarkers in a large pt population (target enrollment: 720 pts; NCT01712789). Methods: Eligible pts have refractory or relapsed and refractory disease, having failed BORT and LEN and received adequate prior alkylator therapy. Key exclusion criteria include absolute neutrophil count < 800/μL, platelet count < 75,000 or 30,000/μL (for pts with < 50% or > 50% of bone marrow nucleated cells as plasma cells, respectively), creatinine clearance < 45 mL/min, hemoglobin < 8 g/dL, and peripheral neuropathy > grade 2. POM is administered 4 mg D1-21/28-day cycle and LoDEX 40 mg/day (20 mg for pts aged > 75 yrs) on D1, 8, 15, and 22 until progressive disease or unacceptable toxicity. All pts receive low-dose ASA or equivalent thromboprophylaxis. Upon Tx discontinuation, follow-up will continue up to 5 yrs from enrollment of last pt for survival, second primary malignancies, and subsequent anti-MM Tx. The primary endpoint is safety. Secondary endpoints include POM exposure, PK, efficacy (overall response rate, time to response, duration of response, PFS, time to progression, OS, and cytogenetics). Cytogenetics are collected at initial diagnosis, study entry, and upon discontinuation to better understand the evolution of cytogenetics throughout the disease course and elucidate the role of POM in pts with different cytogenetic profiles. As exploratory endpoints, bone marrow and blood samples are collected for biomarker analysis to predict response or resistance to POM Tx. As of Jan 22, 2014, 400 pts have been enrolled and enrollment continues. Clinical trial information: NCT01712789.
P52 Epidemiology of Occupational Extrinsic Allergic Alveolitis reported to SWORD 1996–2014: Abstract P52 Table 1
Authors: CM Barber, M Carder, R Agius
Journal: Thorax (2015)

<h3>Introduction</h3> Worldwide, the true epidemiology of occupational EAA is poorly understood. Data from national reporting schemes offers one method of examining the changing demographics of this disease, and comparing the most commonly reported causes. <h3>Methods</h3> Data was obtained for all cases of occupational EAA reported to the UK Surveillance of Work-related and Occupational Respiratory Disease (SWORD) scheme since 1996. The likely causative agents for each reported case were grouped into categories, and data compared for the earliest and latest available 5-year time periods (1996–2000 and 2010–2014). An estimate of the annual incidence of occupational EAA was calculated from the estimated number of cases in each time period divided by the average UK working population at that time (data from the Office for National Statistics). <h3>Results</h3> Data for the early and late 5-year time periods are presented in Table 1. The estimated incidence of occupational EAA was similar for the two time periods, but there has been a notable change in reported causation. Occupational EAA due to metalworking fluid, coolant or oil mist exposure has become the most commonly reported cause, responsible for almost a third of all cases. Over the same time period, EAA in mushroom workers has fallen from the joint commonest cause to no reported cases at all. <h3>Discussion</h3> The estimated annual incidence of occupational EAA in the UK has remained relatively stable at approximately 1–2 cases per million workers. Although this is likely to represent an underestimate, it is similar to the estimated incidence from reporting schemes in Australia, Catalonia, and the Czech Republic, but an order of magnitude lower than that reported in Finland. Over the last 20 years, EAA due to metalworking fluid exposure has emerged as the most commonly reported cause in the UK. This change has not been noted in other published reporting schemes, where EAA due to agricultural exposures remains the most common aetiology.
SoMore trial: Early metabolic response assessment of a sorafenib (SOR) and capecitabine (CAP) combination in chemorefractory metastatic colorectal cancer (mCRC).
Authors: Amélie Deleporte, Alain Hendlisz, Camilo Garcia, Thierry Delaunoit, Raphael Maréchal, Marc Peeters, Stephane Holbrechts, Marc Van Den Eynde, Ghislain Houbiers, Bertrand Filleul, Jean-Luc Van Laethem, Christian Diego Rolfo, Marie Diaz, Renaud Lhommel, Gauthier Demolin, Michel Moreau, Lieveke Ameye, Marianne Paesmans, Martine J. Piccart-Gebhart, Patrick Flamen
Journal: Journal of Clinical Oncology (2014)

524 Background: The SOR-CAP combination has shown clinical activity in several phase I-II trials involving metastatic breast cancer and mCRC patients (pts). SoMore aims to substantiate the combination’s effects in mCRC refractory to all medications and the predictive value of early metabolic response (MR) on survival. Methods: SoMore (EUDRACT 2010-023695-91) has 2 coprimary objectives: 1) to demonstrate an overall survival (OS) rate at 6 months (mths) &gt; 30%, and 2) to compare OS between pts with and without MR. CAP was given at 1700 mg/m²/day (D), 2 weeks out of 3. SOR was administered at 600mg/D for the first cycle, then at 800mg/D until progression or unacceptable toxicity. FDGPET-CT was performed at baseline and before the 2nd cycle. MR analysis was centralized and blinded for the investigators. Results: From February to October 2011, 92 eligible pts were prospectively recruited in 6 Belgian centers: M/F: 54%/46%; ECOG PS 0/1: 55%/45%; median age: 61. A median of 5 treatment cycles were given (0-28+). Grade 3-4 toxic reactions were reported in 61.2%, mainly fatigue (18%), hand-foot skin reaction (14%) and diarrhea (11%), but no toxic death. 6.9% of the pts stopped therapy due to toxicity. 6 mths OS was 71% (95% CI: 61%-79%), significantly &gt;30% (p&lt;0.001). 47% of the 79 pts evaluable for metabolic assessment showed homogeneous MR (HMR) of all metastatic lesions, 32% mixed MR and 21% homogeneous non-MR. Median overall OS and PFS of the intent-to-treat population and of pts with and without HMR are shown in the table below. Hazard ratio for HMR was 0.34 (95% CI, 0.21 to 0.56) p-value &lt;0.001 for PFS and 0.59 (95% CI, 0.37 to 0.96) p-value 0.03 for OS. Conclusions: These data suggest robust efficacy for the SOR-CAP combination in heavily pretreated mCRC, associated with high but manageable toxicity. Early MR assessment, by detecting unresponsive lesions within the whole body tumoral load, is able to capture the pts’ likelihood of benefit, opening the path to personalized medicine. Clinical trial information: NCT01290926. [Table: see text]
The nursing profession's coming of age
Authors: David L. Bisset, Robbie S. Coull, Susan Duncan, Memo G. S. Spathis, Anjan Chakraborty, Trefor J. Roscoe, Vinay P. Rao, Ayan S Panja, Anthony Papagiannis, Sandra Magennis, Mark Davies
Journal: BMJ (2006)

Editor—Young describes the coming of age of the nursing profession. All professions and occupations are human creations and therefore are subject to change. With the widening of roles of many professions, it becomes harder to define what a doctor can do that can’t be done by an appropriately trained member of another profession. Perhaps major surgery and certifying cause of death are all that remains. With the increasing difficulty of getting junior doctors to do anything that may be regarded as work (rather than education) we doctors may be engineering the abolition of our profession, and we may move from distinct professions to practitioners from varied backgrounds being trained for a particular function.
P2-168: Is 2D versus 3D planning detrimental for local control and survival in preoeperative radiochemotherapy in NSCLC?
Authors: Francesc Casas, Núria Viñolas, Josep Maria Gimferrer, Ferran Ferrer, Enric Carcereny, Ramon Marrades, Marcelo Sanchez, Francisco Lomeña, Jordi Marruecos
Journal: Journal of Thoracic Oncology (2007)
P2-293: Final results of a phase 1/2 study of biweekly pemetrexed and gemcitabine in patients with advanced NSCLC
Authors: Arkadiusz Dudek, Tim Larson, Michael McCleod, Daniel J. Schneider, Jonathan E. Dowell, Tarit K. Banerjee, Kishan J. Pandya, Jane Bromund, Kelly Kirsch, Coleman K. Obasaju
Journal: Journal of Thoracic Oncology (2007)
Superior performance of N‐terminal pro brain natriuretic peptide for diagnosis of acute decompensated heart failure in an Asian compared with a Western setting
Authors: Irwani Ibrahim, Win Sen Kuan, Chris Frampton, Richard Troughton, Oi Wah Liew, Jenny Pek Ching Chong, Siew Pang Chan, Li Ling Tan, Wei Qin Lin, Chris J. Pemberton, Shirley Beng Suat Ooi, A. Mark Richards
Journal: European Journal of Heart Failure (2016)
Efficacy and Safety of Tolvaptan in Patients Hospitalized With Acute Heart Failure
Authors: G. Michael Felker, Robert J. Mentz, Robert T. Cole, Kirkwood F. Adams, Gregory F. Egnaczyk, Mona Fiuzat, Chetan B. Patel, Melvin Echols, Michel G. Khouri, James M. Tauras, Divya Gupta, Pamela Monds, Rhonda Roberts, Christopher M. O’Connor
Journal: Journal of the American College of Cardiology (2016)
Long-term effects of home visitation on maternal life course and child abuse and neglect. Fifteen-year follow-up of a randomized trial
Authors: D. L. Olds
Journal: JAMA (1997)

omen's use of welfare and number of subsequent children were based on self-report; their arrests and convictions were based on self-report and archived data from New York State. Verified reports of child abuse and neglect were abstracted from state records. Main Results.\p=m-\Du ring the 15-year period after the birth of their first child, in contrast to women in the comparison group, women who were visited by nurses during pregnancy and infancy were identified as perpetrators of child abuse and neglect in 0.29 vs 0.54 verified reports (P<.001). Among women who were unmarried and from households of low socioeconomic status at initial enrollment, in contrast to those in the comparison group, nurse-visited women had 1.3 vs 1.6 subsequent births (P=.02), 65 vs 37 months between the birth of the first and a second child (P=.001), 60 vs 90 months' receiving Aid to Families With Dependent Children (P=.005), 0.41 vs 0.73 behavioral impairments due to use of alcohol and other drugs (P=.03), 0.18 vs 0.58 arrests by self-report (P<.001), and 0.16 vs 0.90 arrests disclosed by New York State records (P<.001). Conclusions.\p=m
Near-infrared light-triggered release of small molecules for controlled differentiation and long-term tracking of stem cells in vivo using upconversion nanoparticles
Authors: Jinming Li, Wayne Yuk-Wai Lee, Tianyi Wu, Jianbin Xu, Kunyu Zhang, Dexter Siu Hong Wong, Rui Li, Gang Li, Liming Bian
Journal: Biomaterials (2016)
Interluekin-10 (IL-10) Promoter Gene Polymorphism (−819*C) Associated with Poor Clinical Outcome in DLBCL Patients Treated with R (Rituximab)-CHOP Regimen as a First Line.
Authors: Yeo-Kyeoung Kim, Hee-Nam Kim, Je-Jung Lee, Deok-Hwan Yang, Il-Kwon Lee, Kyeoung-Soo Park, Hyeoung-Joon Kim
Journal: Blood (2005)
A Phase II Study of the HDAC Inhibitor Givinostat In Combination with Hydroxyurea In Patients with Polycythemia Vera Resistant to Hydroxyurea Monotherapy
Authors: Alessandro Rambaldi, Guido Finazzi, Alessandro M. Vannucchi, Vincenzo Martinelli, Francesco Rodeghiero, Francesco Nobile, Giorgina Specchia, Enrico Maria Pogliani, Odoardo Maria Olimpieri, Giuseppe Fioritoni, Caterina Musolino, Giuseppe Saglio, Piera Sivera, Giovanni Barosi, Silvia Di Tollo, Tiziano Barbui
Journal: Blood (2011)
Zika Virus Disease Cases — 50 States and the District of Columbia, January 1–July 31, 2016
Authors: William L. Walker, Nicole P. Lindsey, Jennifer A. Lehman, Elisabeth R. Krow-Lucal, Ingrid B. Rabe, Susan L. Hills, Stacey W. Martin, Marc Fischer, J. Erin Staples
Journal: MMWR Morbidity and Mortality Weekly Report (2016)

Zika virus is a mosquito-borne flavivirus primarily transmitted to humans by Aedes aegypti mosquitoes (1). Zika virus infections have also been documented through intrauterine transmission resulting in congenital infection; intrapartum transmission from a viremic mother to her newborn; sexual transmission; blood transfusion; and laboratory exposure (1-5). Most Zika virus infections are asymptomatic (1,6). Clinical illness, when it occurs, is generally mild and characterized by acute onset of fever, maculopapular rash, arthralgia, or nonpurulent conjunctivitis. However, Zika virus infection during pregnancy can cause adverse outcomes such as fetal loss, and microcephaly and other serious brain anomalies (1-3). Guillain-Barré syndrome, a rare autoimmune condition affecting the peripheral nervous system, also has been associated with Zika virus infection (1). Following the identification of local transmission of Zika virus in Brazil in May 2015, the virus has continued to spread throughout the Region of the Americas, and travel-associated cases have increased (7). In 2016, Zika virus disease and congenital infections became nationally notifiable conditions in the United States (8). As of September 3, 2016, a total of 2,382 confirmed and probable cases of Zika virus disease with symptom onset during January 1-July 31, 2016, had been reported from 48 of 50 U.S. states and the District of Columbia. Most cases (2,354; 99%) were travel-associated, with either direct travel or an epidemiologic link to a traveler to a Zika virus-affected area. Twenty-eight (1%) cases were reported as locally acquired, including 26 associated with mosquito-borne transmission, one acquired in a laboratory, and one with an unknown mode of transmission. Zika virus disease should be considered in patients with compatible clinical signs or symptoms who traveled to or reside in areas with ongoing Zika virus transmission or who had unprotected sex with someone who traveled to those areas. Health care providers should continue to educate patients, especially pregnant women, about the importance of avoiding infection with Zika virus, and all pregnant women should be assessed for possible Zika virus exposure at each prenatal visit (2).
Detection of interleukin-2 is not useful for distinguishing between latent and active tuberculosis in clinical practice: a prospective cohort study
Authors: M. Santin, F. Morandeira-Rego, F. Alcaide, R. Rabuñal, L. Anibarro, R. Agüero-Balbín, X. Casas-Garcia, E. Pérez-Escolano, M.D. Navarro, F. Sánchez, A. Coira-Nieto, M. Trigo-Daporta, A. Martinez-Meñaca, A. Gonzalez-Cuevas, M.D. López-Prieto, A. Domínguez-Castellano, N. Jové, Edu A. Struzka, Joan Climent, Antón Penas-Truque, Abel Pallarés-Sanmartín, Mónica Ríos, Diego J. Pargada-Ferrer, Jesús Agüero-Balbin, Juan F. Rodríguez-Gutiérrez
Journal: Clinical Microbiology and Infection (2016)
Phase II study of gonadotropin-releasing hormone analogue for ovarian function preservation in hematopoietic stem cell transplantation patients.
Authors: Y. Cheng, M. Takagi, A. Milbourne, R. E. Champlin, N. T. Ueno
Journal: Journal of Clinical Oncology (2010)

9025 Background: The incidence of premature ovarian failure (POF) in patients received conventional chemotherapy alone ranges from 40%-70%. However, the incidence increases to 70%-100% in patients undergoing myeloablative chemotherapy with hematopoietic stem cell transplantation (HSCT). Gonadotropin-releasing hormone (GnRH) analogues, such as leuprolide, when given in a continuous-release formulation, will potentially protect the ovary from the toxic effects of the chemotherapy. In non-HSCT settings, the use of GnRH analogues have been shown to reduce the risk of POF to <10%. We conducted a phase II clinical trial based on the hypothesis that leuprolide given before the start of conditioning chemotherapy in HSCT patients would reduce the incidence of POF. Methods: Eligible patients had to be women ≤ 40 yr-old who were HSCT candidates, were premenopausal, and had FSH ≤ 20 IU/L and LH ≤ 20 IU/L. Two 22.5-mg doses of leuprolide delivered in 3-month depot intramuscular injections were given to patients with the first dose given within 2 months prior to HSCT. Patients were followed for return of menstruation and ovarian function tests (FSH, LH, and estradiol) were given every 2 months after day 180 post-transplant. Results: Sixty eligible patients were enrolled in the study. Eleven patients were within 180 days post-transplant and were thus not evaluable yet. Another 11 patients died within 180 days post-transplant without ovarian function status being available. Of the 38 evaluable patients (median age, 25 yrs and median follow-up, 321 days), only 5 regained their ovarian function (13%). When looking at the correlation between regained ovarian function and conditioning regimens before transplant, of the 28 patients who received myeloablative regimens, 4 patients regained ovarian function (14%). However, among the 10 patients who received nonmyeloablative regimens, only 1 patient (10%) regained ovarian function. Conclusions: The use of a leuprolide did not preserve ovarian function in patients who underwent HSCT using either myeloablative or nonmyeloablative regimens. Other ovarian function protective measures need to be investigated for patients undergoing HSCT. No significant financial relationships to disclose.
STING Requires the Adaptor TRIF to Trigger Innate Immune Responses to Microbial Infection
Authors: Xin Wang, Tanmay Majumdar, Patricia Kessler, Evgeny Ozhegov, Ying Zhang, Saurabh Chattopadhyay, Sailen Barik, Ganes C. Sen
Journal: Cell Host & Microbe (2016)
Author’s response to Organisation of Pharmaceutical Producers of India’s reply to his article
Authors: Frederik Joelving
Journal: BMJ (2016)

Thank you for your Response to my recent article on India’s health camps.1 2 I will answer your points below.

You say that drug companies do not control how the health camps are conducted. Nonetheless, pharmaceutical sales representatives, and in some cases technicians, carry out tests at the camps in direct contact with patients. I have witnessed this myself several times, as I note in the …
UK troops to continue to receive mefloquine despite concern over adverse events
Authors: Caroline White
Journal: BMJ (2016)

UK doctors will be allowed to prescribe the antimalarial drug mefloquine to British troops only if they carry out a face-to-face risk assessment and provide evidence that they have offered suitable alternatives, the Ministry of Defence has conceded.

The decision to revise its malaria prevention policy was prompted by a raft of recommendations made by a House of Commons defence committee report into the use of mefloquine (marketed as Lariam) among British military personnel, which was published earlier this year.1 The drug has been linked to adverse reactions, including psychosis.2

The report …
Association of B-Type Natriuretic Peptide With Survival in Patients With Degenerative Mitral Regurgitation
Authors: Marie-Annick Clavel, Christophe Tribouilloy, Jean-Louis Vanoverschelde, Rodolfo Pizarro, Rakesh M. Suri, Catherine Szymanski, Siham Lazam, Pablo Oberti, Hector I. Michelena, Allan Jaffe, Maurice Enriquez-Sarano
Journal: Journal of the American College of Cardiology (2016)
C9-04: The Relatonship between surgical diagnosis and pathological diagnosis of lymph node metastasis
Authors: Hidefumi Takei, Tsutomu Yoshida, Go Furuyashiki, Shin Karita, Yasushi Nagashima, Yoko Nakazato, Yoshihiko Koshiishi, Tomoyuki Goya
Journal: Journal of Thoracic Oncology (2007)
Medical Devices and Adolescents
Authors: Joy H. Samuels-Reid, Judith U. Cope
Journal: JAMA Pediatrics (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Pediatrics HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Pediatrics journal
Clinical Significance of Additional Cytogenetic Abnormalities (ACA) Acquired at the First Relapse in Adult Acute Myeloid Leukemia (AML) Patients
Authors: Hiroaki Shimizu, Akihiko Yokohama, Nahoko Hatsumi, Satoru Takada, Takayuki Saitoh, Hiroshi Handa, Toru Sakura, Yoshihisa Nojima
Journal: Blood (2014)
Genetic Basis for Sex Differences in Obesity and Lipid Metabolism
Authors: Jenny C. Link, Karen Reue
Journal: Annual Review of Nutrition (2017)

Men and women exhibit significant differences in obesity, cardiovascular disease, and diabetes. To provide better diagnosis and treatment for both sexes, it is important to identify factors that underlie the observed sex differences. Traditionally, sex differences have been attributed to the differential effects of male and female gonadal secretions (commonly referred to as sex hormones), which substantially influence many aspects of metabolism and related diseases. Less appreciated as a contributor to sex differences are the fundamental genetic differences between males and females, which are ultimately determined by the presence of an XX or XY sex chromosome complement. Here, we review the mechanisms by which gonadal hormones and sex chromosome complement each contribute to lipid metabolism and associated diseases, and the current approaches that are used to study them. We focus particularly on genetic approaches including genome-wide association studies in humans and mice, -omics and systems genetics approaches, and unique experimental mouse models that allow distinction between gonadal and sex chromosome effects.